Here's Why TherapeuticsMD Jumped 25.6% in September [The Motley Fool]
TherapeuticsMD, Inc. (TXMD)
NASDAQ:AMEX Investor Relations:
ir.therapeuticsmd.com
Company Research
Source: The Motley Fool
Here's Why TherapeuticsMD Jumped 25.6% in September What happened Shares of TherapeuticsMD ( NASDAQ:TXMD Global Market Intelligence According to that update, large insurance companies are continuing to add the company's drug products to their coverage lists, Imvexxy maintained prescription momentum in August, and the CEO bought $80,000 in stock in the third quarter. All of those points contributed to investor optimism that pushed shares of the pharmaceutical company Image source: Getty Images. So what TherapeuticsMD is still in the early stages of commercializing its treatments. The business reported just $. million in revenue in the second quarter, and current full-year guidance is for revenue of at least $9. million. But the company has three drugs on the market with ample growth potential. Imvexxy (launched in August 08), Bijuva (launched in April 09), and Annovera (launching in Q 00) have combined peak annual sales potential of $.8 billion. It will take time to get those drugs co
Show less
Read more
Impact Snapshot
Event Time:
TXMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TXMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TXMD alerts
High impacting TherapeuticsMD, Inc. news events
Weekly update
A roundup of the hottest topics
TXMD
News
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TherapeuticsMD Announces Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
TXMD
Sec Filings
- 3/29/24 - Form 10-K
- 3/29/24 - Form 8-K
- TXMD's page on the SEC website